Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $434,435.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) insider Dana Pizzuti sold 9,500 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $45.73, for a total transaction of $434,435.00. Following the transaction, the insider now owns 27,786 shares in the company, valued at $1,270,653.78. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Dana Pizzuti also recently made the following trade(s):

• On Monday, April 15th, Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $44.47, for a total transaction of $639,256.25.

Crinetics Pharmaceuticals Stock Performance

Shares of CRNX opened at $43.47 on Friday. The company has a 50 day moving average price of $46.32 and a 200-day moving average price of $41.85. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $15.76 and a fifty-two week high of $53.70. The stock has a market capitalization of $3.43 billion, a PE ratio of -11.50 and a beta of 0.64.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its earnings results on Thursday, May 9th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 42.50%. The firm had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.20 million. During the same period in the previous year, the company earned ($0.85) EPS. The company’s revenue was down 76.1% on a year-over-year basis. Equities research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.53 EPS for the current year.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank purchased a new stake in Crinetics Pharmaceuticals during the first quarter valued at approximately $33,000. Quarry LP purchased a new stake in Crinetics Pharmaceuticals during the fourth quarter valued at approximately $36,000. AJOVista LLC purchased a new stake in Crinetics Pharmaceuticals during the fourth quarter valued at approximately $58,000. HighMark Wealth Management LLC acquired a new position in Crinetics Pharmaceuticals during the 4th quarter valued at approximately $151,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Crinetics Pharmaceuticals during the 1st quarter valued at approximately $200,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CRNX shares. Piper Sandler upped their price target on shares of Crinetics Pharmaceuticals from $56.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. Citigroup assumed coverage on shares of Crinetics Pharmaceuticals in a research note on Wednesday, March 6th. They issued a “buy” rating and a $68.00 target price on the stock. Jonestrading upped their target price on shares of Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. JMP Securities restated a “market outperform” rating and issued a $80.00 target price on shares of Crinetics Pharmaceuticals in a research note on Tuesday, June 4th. Finally, Morgan Stanley upped their target price on shares of Crinetics Pharmaceuticals from $50.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, May 23rd. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $62.50.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.